SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

BG-85738

ONC·BeOne Medicines Ltd.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1
Time to market
At least 4-6 years away, assuming successful Phase 1-3 development and regulatory filing. The Phase 1 trial is not expected to complete until September 2028, and the drug has not yet entered Phase 2 or Phase 3 testing.
Why 2/10
No hard, dated catalyst is scheduled for BG-85738 in the next ~12 months. The Phase 1 trial started enrollment in September 2026 and is not expected to complete until September 2028. BG-85738 is one early-stage program within a large, diversified pipeline at a ~$46B market-cap company whose value is overwhelmingly driven by approved products (BRUKINSA) and later-stage assets. Even a positive early readout would have a muted impact on the stock.
Actionable Insight NEUTRAL

No hard, dated catalyst for BG-85738 is expected in the next 12 months. The Phase 1 trial is actively recruiting with estimated primary completion in September 2028. Investors should monitor for any early safety/efficacy data presentations at medical conferences (e.g., ASCO, ESMO, AACR) which could provide early signals, but the drug is a very small component of BeOne's overall value. The key near-term drivers for ONC stock remain BRUKINSA sales trajectory and later-stage pipeline readouts, not BG-85738.

Price Chart

Loading chart...

Executive Summary

BG-85738 is an oral pan-RAS (ON) inhibitor in Phase 1 development by BeOne Medicines Ltd. (Nasdaq: ONC, formerly BeiGene), a large-cap global oncology company with a ~$46B market cap and multiple approved products led by BRUKINSA. The drug targets the active GTP-bound state of KRAS, NRAS and HRAS across a broad range of oncogenic mutations. A first-in-human Phase 1a/1b trial (NCT07746141) began enrolling in September 2026 and is expected to complete by September 2028. Preclinical data suggest potential differentiation versus the now-FDA-approved competitor daraxonrasib (RMC-6236), including comparable efficacy at lower doses and blood-brain barrier penetration. However, BG-85738 is an early-stage, single Phase 1 program within a large, diversified pipeline, and no binary catalyst is scheduled within the next 12 months.

How It Works

BG-85738 is an oral pill designed to block a family of proteins called RAS (including KRAS, NRAS, and HRAS) that are overactive in about 25% of all cancers. When RAS proteins are stuck in their "on" position due to mutations, they tell cancer cells to grow uncontrollably. BG-85738 binds directly to the active form of these proteins and turns them off, potentially stopping tumor growth across many cancer types regardless of which specific RAS mutation is present.

Trial Status

First-in-human Phase 1a/1b study (NCT07746141) began enrolling on September 2, 2026. The trial is actively recruiting 100 participants with advanced or metastatic RAS-mutant solid tumors across sites in Australia. Part A is dose escalation as monotherapy; Part B and Part C evaluate combination therapy with tislelizumab or cetuximab, and monotherapy dose expansion. Estimated primary completion date is September 30, 2028.

The Two-Sided Case

▲ Bull Case4
Preclinical data suggest BG-85738 may be a best-in-class pan-RAS inhibitor: 1 mg/kg showed comparable antitumor efficacy to 25 mg/kg of the now-approved competitor daraxonrasib (RMC-6236) in KRAS G12V mouse models, per Chinese biotech media reports citing company data.
BG-85738 demonstrated blood-brain barrier penetration in preclinical models (mouse Kpuu of 39%), which could be a meaningful differentiation versus competitors if confirmed in humans, potentially opening CNS metastasis indications.
The pan-RAS (ON) inhibitor class has clinical proof of concept: Revolution Medicines' daraxonrasib (RMC-6236) was FDA approved on August 26, 2026 for metastatic pancreatic cancer, validating the mechanism and creating a large addressable market.
BeOne Medicines has deep oncology expertise and financial resources (Q3 2026 revenue of $1.9B) to advance the program without near-term funding concerns.
▼ Bear Case4
BG-85738 is in very early Phase 1 testing with no human efficacy or safety data yet. Most oncology drugs that enter Phase 1 fail to reach approval, and the high failure rate for novel mechanisms is well documented.
The competitive landscape is rapidly evolving: Revolution Medicines' daraxonrasib (RMC-6236) was FDA approved in August 2026, and multiple other pan-RAS inhibitors from large pharma and biotech are in development, creating a crowded field by the time BG-85738 could reach market.
BG-85738 is a tiny component of BeOne Medicines' value. The company has a ~$46B market cap, multiple approved drugs (BRUKINSA generating over $1B quarterly in the US alone), and a broad pipeline of over a dozen clinical-stage programs. Even a successful Phase 1 readout would have minimal impact on the stock.
The Phase 1 trial is not expected to complete until September 2028, meaning no binary catalyst from this program for approximately two years. Investors have no near-term de-risking event to trade on.

Upcoming Catalysts

  • No hard, dated catalyst for BG-85738 in the next 12 months. The Phase 1 trial is actively recruiting with estimated completion in September 2028. Potential early data presentations at medical conferences (ASCO, ESMO, AACR) could occur but are not yet scheduled.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BeOne Medicines Ltd. 8-K ONC ·Originating report

Sources · 12

Hover a chip for the title
1 clinicaltrials.gov2 beonemedicines.com3 synapse.patsnap.com4 vcbeathealth.com5 ir.beonemedicines.com6 biospace.com7 fda.gov8 ir.revmed.com9 stockanalysis.com10 marketbeat.com11 tipranks.com12 gosset.ai